Eli Lilly’s EBGLYSS shows breakthrough results in children with severe eczema

The company announced positive topline data from the Phase 3 ADorable-1 trial

Merck doubles down on cardio-pulmonary breakthroughs

At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes

This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin

Finerenone hits major goal in Phase III FIND-CKD trial

There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk

China’s NMPA approves Zydus-licensed anaemia drug Desidustat

Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients

Caplin Steriles gets USFDA approval for potassium phosphates injection

AI boom, screen overload quietly stealing India’s sleep, new survey warns

FDA nod to LifeVac De Novo, paving for next-generation anti-choking device

The FDA classified LifeVac as a Class II medical device

FDA nod to first treatment for rare genetic brain disorder

The approval comes after a systematic review of published literature

EnteroBiotix completes enrollment in landmark microbiome trial for stem cell transplant patients

The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation